Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
QuintilesIMS
Fuji
Cerilliant
Queensland Health
AstraZeneca
Chinese Patent Office
Cipla
Colorcon

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020973

« Back to Dashboard

NDA 020973 describes ACIPHEX, which is a drug marketed by Eisai Inc and Cerecor Inc and is included in two NDAs. It is available from four suppliers. Additional details are available on the ACIPHEX profile page.

The generic ingredient in ACIPHEX is rabeprazole sodium. There are thirty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the rabeprazole sodium profile page.
Summary for 020973
Tradename:ACIPHEX
Applicant:Eisai Inc
Ingredient:rabeprazole sodium
Patents:0
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020973
Mechanism of ActionProton Pump Inhibitors
Medical Subject Heading (MeSH) Categories for 020973
Suppliers and Packaging for NDA: 020973
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973 NDA Physicians Total Care, Inc. 54868-4185 E 54868-4185-0
ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973 NDA Physicians Total Care, Inc. 54868-4185 E 54868-4185-1

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, DELAYED RELEASE;ORALStrength10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:May 29, 2002TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength20MG
Approval Date:Aug 19, 1999TE:ABRLD:Yes

Expired US Patents for NDA 020973

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973-002 Aug 19, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Eisai Inc ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973-001 May 29, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Eisai Inc ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973-002 Aug 19, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Eisai Inc ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973-001 May 29, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Queensland Health
Johnson and Johnson
Cantor Fitzgerald
Merck
Daiichi Sankyo
Chubb
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.